Hims stock fell Tuesday following a mixed third-quarter report after the telehealth giant said it's in discussions with Novo NordiskNVO to sell Wegovy shots. Hims & Hers HealthHIMS reported $599 ...
Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...
Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...
The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...
Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform. The discussions are about both ...
Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...
The telehealth platform was hit earlier this year by the Food & Drug Administration declaring there was no longer a shortage of Ozempic or Wegovy, the GLP-1 drugs sold by Novo Nordisk (NYSE:NVO) for ...
Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results